The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Novartis (NVS) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Novartis is a member of the Medical sector. This group includes 974 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sec ...

Johnson & Johnson (JNJ) closed the most recent trading day at $178.41, moving +1.49% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.85%. On the other hand, the Dow registered a gain of 1.36%, and the technology-centric Nasdaq increased by 0.72%. Shares of the world's biggest maker of health care products have appreciated by 0.79% over the course of the past month, underperforming the Medical sector's gain of 6.01%, and the S&P 500's gain of 2.38%.Th ...

The drug and biotech sector is facing multiple headwinds. President Trump has warned of heavy tariffs, as high as 250%, on pharmaceutical imports. Trump’s repeated threats to impose tariffs on pharmaceutical imports are aimed at pushing American pharma companies to shift pharmaceutical production back to the United States, primarily from European and Asian countries. Trump has said that drugmakers have about one to one and a half years to bring production back to the United States before the new tariffs are ...

Group 1: Earnings Performance - Eli Lilly reported quarterly earnings of $6.31 per share, exceeding the Zacks Consensus Estimate of $5.61 per share, and up from $3.92 per share a year ago, representing an earnings surprise of +12.48% [1] - The company posted revenues of $15.56 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.48%, compared to year-ago revenues of $11.3 billion [2] - Over the last four quarters, Eli Lilly has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Eli Lilly shares have declined approximately 3.3% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is $6.22 on revenues of $15.74 billion, and for the current fiscal year, it is $22.05 on revenues of $60.43 billion [7] Group 3: Industry Context - The Large Cap Pharmaceuticals industry, to which Eli Lilly belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Company Overview - Johnson & Johnson (JNJ) is headquartered in New Brunswick and operates in the Medical sector [3] - The stock has experienced a price change of 18.06% since the beginning of the year [3] Dividend Information - Johnson & Johnson currently pays a dividend of $1.30 per share, resulting in a dividend yield of 3.05% [3] - The Large Cap Pharmaceuticals industry's yield is 3.11%, while the S&P 500's yield is 1.49% [3] - The company's annualized dividend of $5.20 has increased by 5.9% from the previous year [4] - Over the last 5 years, Johnson & Johnson has raised its dividend 5 times, averaging an annual increase of 5.37% [4] - The current payout ratio is 52%, indicating that the company paid out 52% of its trailing 12-month EPS as dividends [4] Earnings Expectations - The Zacks Consensus Estimate for 2025 earnings is $10.86 per share, with an expected increase of 8.82% from the previous year [5] Investment Considerations - Johnson & Johnson is viewed as an attractive dividend play and a compelling investment opportunity, holding a Zacks Rank of 2 (Buy) [6]

Company Performance - Amarin (AMRN) has returned approximately 56% since the beginning of the calendar year, significantly outperforming the average loss of 6.1% in the Medical sector [4] - The Zacks Consensus Estimate for AMRN's full-year earnings has increased by 50.1% over the past quarter, indicating improved analyst sentiment and a more positive earnings outlook [3] Sector and Industry Comparison - Amarin is part of the Medical sector, which includes 979 individual stocks and currently holds a Zacks Sector Rank of 7 [2] - Within the Medical - Biomedical and Genetics industry, which consists of 489 companies, Amarin ranks 144 in the Zacks Industry Rank, outperforming the average gain of 0.2% in this group [5] - Bayer Aktiengesellschaft (BAYRY), another stock in the Medical sector, has a year-to-date return of 63.1% and also holds a Zacks Rank of 2 (Buy) [4][5] Investment Outlook - Investors interested in Medical stocks should continue to monitor Amarin and Bayer Aktiengesellschaft, as both stocks are expected to maintain their strong performance [6]

分组1 - Pfizer reported quarterly earnings of $0.78 per share, exceeding the Zacks Consensus Estimate of $0.58 per share, and showing an increase from $0.6 per share a year ago, resulting in an earnings surprise of +34.48% [1] - The company achieved revenues of $14.65 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.35%, and up from $13.28 billion year-over-year [2] - Over the last four quarters, Pfizer has consistently surpassed consensus EPS estimates four times and revenue estimates three times [2] 分组2 - The stock has underperformed the market, losing about 11.3% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.86 on revenues of $17.37 billion, and for the current fiscal year, it is $3.07 on revenues of $63.4 billion [7] - The Large Cap Pharmaceuticals industry, to which Pfizer belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Company Overview - Eli Lilly (LLY) closed at $762.95, reflecting a -5.59% change from the previous day, which is worse than the S&P 500's daily loss of 0.3% [1] - Over the last month, Eli Lilly's shares increased by 3.67%, outperforming the Medical sector's gain of 0.76% and the S&P 500's gain of 3.64% [1] Upcoming Earnings - The upcoming earnings report for Eli Lilly is expected on August 7, 2025, with an anticipated EPS of $5.61, representing a 43.11% increase year-over-year [2] - Revenue is forecasted to be $14.75 billion, indicating a 30.49% growth compared to the same quarter of the previous year [2] Full Year Projections - For the full year, Zacks Consensus Estimates project earnings of $22.05 per share and revenue of $60.55 billion, reflecting increases of +69.75% and +34.43% respectively from the prior year [3] - Recent changes to analyst estimates for Eli Lilly are noted as indicators of optimism regarding the business outlook [3] Stock Performance and Valuation - The Zacks Rank system, which assesses estimate changes, indicates that Eli Lilly currently holds a Zacks Rank of 3 (Hold) [5] - The Zacks Consensus EPS estimate has increased by 0.48% in the past month [5] - Eli Lilly's Forward P/E ratio is 36.64, which is a premium compared to its industry's Forward P/E of 14.23 [5] Industry Context - Eli Lilly operates within the Large Cap Pharmaceuticals industry, which has a Zacks Industry Rank of 62, placing it in the top 26% of over 250 industries [7] - The average PEG ratio for the Large Cap Pharmaceuticals industry is 1.24, while Eli Lilly's PEG ratio is 1.15 [6]

Merck (MRK) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $2.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5.97%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $2.15 per share when it actually produced earnings of $2.22, delivering a surprise of +3.26%.Over the last four quarters, the comp ...

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.Cash flow can come from bond interest, interest from other types of investments, and, of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that mea ...